Assessing Addiction: Concepts and Instruments by Samet, Sharon et al.
fficient, organized assessment of substance use disorders is essential for clinical research, treatment planning, and referral
to adjunctive services. In this article, we discuss the basic concepts of formalized assessment for substance abuse and
addiction, as established by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, and describe six
widely used structured assessment instruments. Our aim is to help researchers and clinical programs identify the instruments
that best suit their particular situations and purposes.
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Assessing Addiction: Concepts and Instruments
T
he appropriate way to assess a substance use disorder depends on the
objective. Unstructured clinical interviews serve well enough for many
purposes, such as satisfying third-party diagnostic requirements for reim-
bursement. For many essential clinical and research purposes, however, only struc-
tured (scripted) interviews afford sufficient information and reliability. Structured
instruments assist treatment planning by providing a standardized comparison
of a patient’s characteristics with those of patients who have benefited from inter-
ventions in clinical trials. Clinicians also obtain a comprehensive, objective pic-
ture of the auxiliary services the patient may need to benefit maximally from treat-
ment. In research, these instruments yield the diagnostic consistency that is
indispensable to avoid misclassifying patients and compromising the interpre-
tation of research results.
This article aims to help clinicians and researchers choose the structured assess-
ment instruments appropriate for their needs. For six widely used instruments,
we describe the validity and reliability characteristics; administration procedures;
training requirements; and advantages and disadvantages based on patient pop-
ulation, treatment orientation, and staff skills. The instruments are the
• Addiction Severity Index (ASI);
• Composite International Diagnostic Interview (CIDI);
• Structured Clinical Interview for DSM-IV (SCID);
• Alcohol Use Disorders and Associated Disabilities Interview Schedule (AUDADIS);
• Psychiatric Research Interview for Substance and Mental Disorders (PRISM);
and
• Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA).2 0 •   A D D I C T I O N   S C I E N C E   &   C L I N I C A L   P R A C T I C E — D E C E M B E R   2 0 0 7
WHY CHOOSING THE RIGHT INSTRUMENT
MATTERS
Dr. A. Thomas McLellan, principal developer of the
ASI, has often contrasted two patients to illustrate the
clinical importance of thorough assessments, such as
those yielded by the ASI. One patient, a physician, is
severely physiologically addicted to opiates. The other,
a young woman, has a milder physiological addiction.
An assessment that focuses narrowly on drug abuse his-
tory might stop here, leaving the impression that the
physician faces the greater challenge to recovery. A more
thorough evaluation, however, finds that the physician’s
interpersonal relationships, although troubled, are still
in place, and he is still working. The young woman,
on the other hand, has no social supports except other
drug abusers, is unemployed, and has never kept a job
for long. In fact, she is the one with greater service needs—
in particular, training in social and occupational skills.
In research, an appropriate assessment instrument
can make the difference between null and significant
findings. A recent review of trials to determine whether
tricyclic antidepressants can help substance abusers with
comorbid depression provides an illustrative example
(Nunes and Levin, 2004). Early trials demonstrated 
little or no benefit from the medications. These trials
admitted patients based on their current depressive symp-
toms as itemized in instruments such as the Hamilton
Depression Scale (Hamilton, 1960) or the Beck Depression
Inventory (Beck et al., 1961). Participants would have
included some individuals who had comorbid major
depression and others who were experiencing tran-
sient low moods related to intoxication, withdrawal, or
stress reactions. More recent studies, in contrast, admit-
ted only individuals who met formal diagnostic criteria
for major depressive disorder, which include persistent
symptoms over a period of time. Some recent studies
also delayed assessment until candidates had been absti-
nent for a week to ensure that they were past withdrawal.
In these more uniform populations, the medications
consistently alleviated patients’ depression and also mod-
estly improved their substance abuse outcomes.
GENERAL FEATURES OF ASSESSMENT
INSTRUMENTS
The assessment instruments we will discuss, with the
exception of the ASI, all elicit the information required
to diagnose substance use disorders and other psychi-
atric disorders according to the criteria of the Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition,
Text Revision(DSM-IV; American Psychiatric Association,
2000). Those criteria, the product of more than 30 years
of development and testing, now set the standard for
both research and clinical assessment (see “The DSM
and Standardized Assessment”). Where the instruments
differ is in
• Format—that is, whether they are fully structured or
semi-structured;
• The particular clinical or research objectives they
can serve;
• Reliability and validity for selected uses (see “Reliability
and Validity”);
• Convenience features, such as modularity and avail-
ability in computer-based formats; and
• Training requirements.
Fully Structured Versus Semi-Structured Formats
A fully structured assessment instrument is a script. It
specifies the questions the interviewer is to ask, exactly
as written, as well as a choice of responses for the inter-
viewee. When asking the questions, the interviewer skips
some, based on patient characteristics or previous responses,
and avoids adding probes of his or her own. A semi-
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structured instrument similarly lists questions to be read
verbatim, but also allows the interviewer to add followup
queries based on his or her clinical interpretation of the
interviewee’s initial response.
Both formats have advantages and disadvantages.
Fully structured interviews are economical. They require
no clinical judgment, so trained lay interviewers can
administer them. They generally take less time to admin-
ister. Many large research studies and large treatment
facilities use fully structured instruments, because staff
members with little experience can perform the initial
and followup assessments. Semi-structured interviews,
in contrast, through their open-ended probes, provide
greater detail on the client’s status.
Convenience Features
Many assessment instruments are modular, permit-
ting flexibility in the choice of sections used and diag-
noses assessed. Thus, for example, researchers or clini-
cians who do not encounter psychotic individuals because
of program regulations or a research protocol may omit
a psychosis module.
Several structured and semi-structured diagnostic
interviews are available in computer-assisted formats.
Interviewers read questions to interviewees and enter
responses into a computer rather than a paper form. This
reduces administration time and rater error, as the
program automatically skips or adjusts the wording of
questions based on patients’ previous responses. Further,
computerized administration saves many hours of
data entry and avoids the errors that can occur in trans-
ferring data from paper into a computer database for
analysis. Computerizing the logic of the interview also
reduces the need for post-interview data cleaning. The
data go directly into a database that can immediately
generate reports and statistics.
A BASIC MENU OF ASSESSMENT 
INSTRUMENTS
Of the instruments we discuss here, the ASI and CIDI
make up the common assessment battery of the National
Institute on Drug Abuse (NIDA) Clinical Trials Network
(CTN), which conducts studies to evaluate evidence-
based treatment interventions in widely diverse 
community-based treatment settings and patient pop-
ulations nationwide. Prior to adopting these measures,
a CTN workgroup evaluated many measures for relia-
bility, validity, efficiency, and suitability for widespread
use in nonresearch settings.
RELIABILITY AND VALIDITY
An instrument’s reliability and validity are critical to its value. All the
instruments discussed in this article are highly reliable and valid, but the
extent of their reliability or validity may differ in particular situations.
Reliability
The question of reliability is: Will users of the instrument consistently
reach the same diagnostic conclusions? A straightforward and rigorous
way to answer this question is the test-retest method. Two or more clini-
cians use the instrument to conduct independent assessments of the
same patient, and the degree of correlation among their findings is calcu-
lated. The standard statistical measure of the degree of the clinicians’
agreement, the kappa coefficient, equals 1 if agreement is complete and
less than zero when agreement is no greater than chance might produce
(Cohen, 1960). Generally, a test-retest kappa score of 0.75+ indicates
excellent reliability; 0.60 to 0.74 is good; 0.40 to 0.59 is fair; and less than
0.40 is poor (Fleiss, 1981).
Validity
The question of validity is: Does the instrument truly and unambiguously
assess the condition it is designed to evaluate? This question has more
dimensions than the estimation of reliability; accordingly, validity is esti-
mated with a number of methods.
The widely used SCID was the first standardized
psychiatric interview based on the DSM and has been
updated to correspond to the most current DSM cri-
teria. The AUDADIS, PRISM, and SSADDA were
specifically designed for substance abuse research, but
are adaptable for clinical purposes, too.
Brief descriptions of these instruments follow. For a
summary comparison of their properties, see Table 1. 
The Addiction Severity Index
The ASI (McLellan et al., 1980, 1992) screens for prob-
lems and impairments that commonly accompany drug
abuse and dependence. These include, among others,
interpersonal difficulties with family, friends, and co-
workers; medical conditions such as hepatitis B and C,
HIV/AIDS, sexually transmitted diseases, alcoholic liver
disease, acute myocardial infarction, pneumonia, and
metabolic and endocrine complications (Kresina et
al., 2004; Mertens et al., 2003); and legal troubles. The
ASI provides information that clinicians can use to 
address these problems with appropriate interventions
or referrals.
The semi-structured ASI evaluates patients’ func-
tioning and lifetime experiences in seven domains: (1)
medical conditions, (2) employment/support, (3) use
of alcohol and drugs, (4) legal issues, (5) family history,2 2 •   A D D I C T I O N   S C I E N C E   &   C L I N I C A L   P R A C T I C E — D E C E M B E R   2 0 0 7
THE DSM AND STANDARDIZED ASSESSMENT
T
he year 1980 saw the publication of an epochal document in psychiatry: Diagnostic and Statistical Manual of Mental Disorders, 3rd
Edition (DSM-III; American Psychiatric Association, 1980). The DSM-III provided clinicians and researchers with standardized
definitions and diagnostic criteria for more than 200 psychiatric disorders, including substance abuse and dependence disor-
ders. Prior to this publication, clinicians and researchers commonly used the same diagnostic terms to mean different things, and cli-
nicians often disagreed on whether patients had specific disorders (Spitzer, Endicott, and Robins, 1975; Spitzer and Fleiss, 1974).
Substance abuse professionals engaged in semantic debates over the definition of addiction—even over the very existence of such a
condition.
Following the publication of the DSM-III, diagnostic criteria were included in the mental disorders section of the International Classifica-
tion of Diseases, 10th Edition (ICD-10; World Health Organization, 1993). The ICD-10 is widely used outside the United States to define
psychiatric diagnoses.
Substance Use Disorders in DSM-IV
The current edition of the DSM, DSM-IV-TR, sets diagnostic criteria for two types of substance use disorder: dependence and abuse.
Some patients seeking treatment report too few symptoms to meet the criteria for either diagnosis. In these cases, the specific symp-
toms, symptom clusters, and the severity of associated problems can inform effective strategies for intervention and management.
The ICD-10 criteria for substance dependence are similar to those of the DSM-IV. The ICD-10 counterpart to abuse is called “harmful
use” and is less specific.
Substance Dependence
Drug or alcohol dependence is diagnosed by documenting that a patient has experienced at least three of seven criteria for a particular
substance within a 12-month period. The criteria are:
• Tolerance
• Withdrawal
• Substance often taken in larger amounts or over longer period than intended
• Persistent desire or unsuccessful efforts to cut down or control use
• Great deal of time spent in activities necessary to obtain, use, or recover from the substance
• Important social, occupational, or recreational activities given up or reduced
• Continued use despite knowledge of having a persistent or recurrent physical or psychological problem likely to have been caused 
or exacerbated by the substance
Although the DSM-IV provides no standards for dependence severity, clinicians may specify “with physiological dependence” or 
“with withdrawal” to indicate the presence of tolerance (i.e., the need for higher doses to achieve intoxication or other desired effects).
Withdrawal, in particular, predicts medical problems and poor outcome (Hasin et al., 2000; Schuckit et al., 2003). Alternatively, a
symptom or criteria count can function as a measure of dependence severity (Hasin et al., 2006b).
The DSM-IV lists substance-specific intoxication and withdrawal symptoms for most of the common classes of drugs. Two exceptions
are hallucinogens and cannabis, neither of which had a known withdrawal syndrome at the time of the document’s publication. Plan-
ners for the DSM-V are considering the addition of a withdrawal syndrome for cannabis. In anticipation of such a potential change, the
CIDI and AUDADIS interviews contain items related to possible marijuana withdrawal.
Test-retest studies have repeatedly shown good to excellent reliability for the diagnosis of substance dependence with the DSM-IV
(Bucholz et al., 1995; Chatterji et al., 1997; Easton et al., 1997; Grant et al., 1995, 2003; Hasin et al., 1996, 1997a; Horton, Compton, and
Cottler, 2000; Williams et al., 1992). The DSM-IV substance dependence diagnosis also shows good validity in two forms of multi-
method comparisons. One compares ICD-10, DSM-IV, and DSM-III-R diagnoses obtained from a single diagnostic interview (Grant,
1993; Hasin et al., 1997b; Schuckit et al., 1994). The other compares diagnoses from a single system (such as DSM-IV) produced by dif-
ferent diagnostic interviews (Cottler et al., 1997; Pull et al., 1997).
Studies of families with alcohol problems have validated the criteria for the substance dependence diagnosis. A family history of alco-
hol problems is strongly associated with DSM-IV alcohol dependence (Hasin et al., 1997c; Hasin and Paykin, 1999). In addition, animal
models support the validity of many elements of dependence (Robinson, 2004; Tapper et al., 2004), and neuroscientists and geneti-
cists are finding links to biological variations that increase or reduce the risk for dependence (e.g., Edenberg et al., 2004; Hogg and
Bertrand, 2004).R E S E A R C H   R E V I E W — A S S E S S I N G   A D D I C T I O N   •   2 3
Substance Abuse
Patients who do not meet the criteria for substance dependence may be diagnosed with substance abuse if they report experiencing one
or more of four abuse symptoms repeatedly over a 12-month period. The symtoms are: 
• Failure to fulfill major obligations at work, school, or home
• Recurrent use in situations in which it is physically hazardous
• Recurrent substance-related legal problems
• Continued use despite persistent social or interpersonal problems
Many clinicians have questioned the separation of substance dependence and substance abuse. Studies have shown that the DSM 
criteria for abuse are less valid than those for dependence. However, these studies diagnosed substance abuse hierarchically, meaning
that an abuse diagnosis was considered to be redundant if dependence was present. Although DSM-IV stipulates this procedure, not
everyone with dependence also meets the criteria for abuse (Hasin and Grant, 2004). Women and minorities appear especially likely to
experience dependence without abuse (Hasin et al., 2005; Hasin and Grant, 2004). Studies that assessed abuse regardless of whether
dependence was present showed better reliability for the criteria for abuse (Bucholz et al., 1995; Canino et al., 1999; Cottler et al., 1997;
Pull et al., 1997). In summary, the DSM-IV hierarchical status of abuse is problematic, but the criteria yield reliable diagnoses. 
DSM-IV and Substance Use Comorbidity
Extensive comorbidity between substance use disorders and other psychiatric disorders has been reported consistently in patients
(Nunes, Hasin, and Blanco, 2004) as well as in the general population (Grant et al., 2004a, 2004b; Regier et al., 1990). Such comorbid-
ity can be serious. For example, studies with acceptable response rates (70 percent or more) and reliable diagnostic assessments have
consistently found an adverse effect of major depression on the outcome of substance use disorders (Hasin, Nunes, and Meydan,
2004). Further, among patients with histories of substance dependence and major depression, the occurrence of a major depressive
episode during periods of sustained abstinence predicts a higher number of suicide attempts (Aharonovich et al., 2002).
To be accurate, assessments must address the fact that substance intoxication and withdrawal can mimic symptoms of depression, 
psychosis, or other independent psychiatric disorders. Accordingly, the DSM-IV distinguishes among “expected effects” of substance 
intoxication or withdrawal, “primary disorders,” and “substance-induced disorders.” A primary disorder is diagnosed if “the symptoms
are not due to the direct physiological effects of a substance” (American Psychiatric Association, 2000). Psychiatric disorders that 
co-occur with substance intoxication or withdrawal can be considered primary if (1) symptoms substantially exceed the expected effects 
of the substance in the amount that was used; (2) there is a personal history of psychiatric symptoms during periods of extended absti-
nence; (3) the onset of psychiatric symptoms clearly preceded the onset of substance use; and (4) symptoms persisted for at least a
month after the cessation of intoxication or withdrawal. Symptoms that are not considered primary fall into the category either of
expected effects of a substance or of a substance-induced disorder that exceeds intoxication or withdrawal effects and deserves inde-
pendent clinical attention. Instrument developers have incorporated this information into some tools, in particular the SSADDA 
and PRISM.
(6) family/social relationships, and (7) psychiatric dis-
orders. The administrator asks the patient to rate his
or her level of distress in each domain during the past
30 days from 0 (none) to 4 (extreme) and independently
rates the patient’s need for treatment in each domain
from 0 (none necessary) to 9 (treatment needed to inter-
vene in a life-threatening situation). Finally, the admin-
istrator calculates a composite score from a subset of the
distress and treatment need responses. This score becomes
the basis for treatment planning. Altogether, the ASI
takes approximately 45 to 60 minutes to administer,
plus 10 to 20 minutes for post-interview scoring.
The ASI’s psychometric properties have been tested
extensively (Alterman et al., 1994; Hodgins and el-
Guebaly, 1992; Joyner, Wright, and Devine, 1996;
Kosten, Rounsaville, and Kleber, 1983; McLellan et al.,
1985; Rogalski, 1987). Several studies have demon-
strated good to excellent reliability and validity for the
instrument (Butler et al., 2001; Hendriks et al., 1989;
Leonhard et al., 2000; Weisner, McLellan, and Hunkeler,
2000). A 2004 summary of studies in multiple patient
groups (Mäkelä) found that the reliability of composite
scores varied from high (Daeppen et al., 1996; McLellan
et al., 1985; Peters et al., 2000) to low (Drake, McHugo,
and Biesanz, 1995; Zanis et al., 1994; Zanis, McLellan,
and Corse, 1997). Three of the seven ASI domains (med-
ical conditions, use of alcohol, and psychiatric disorders)
have high internal consistency across studies, while
the other four are more variable. Correlations between
domains are usually low, except those between the drug
and legal measures and those between the psychiatric
and social impairment measures. The lack of across-the-board correlations is consistent with the ASI’s perspec-
tive, which is that impairment in some domains does
not necessarily entail impairment in others.
The ASI, by itself, may not be a highly reliable screen
for special populations, such as the homeless or dually
diagnosed. For the latter groups, the ASI should be sup-
plemented with instruments that assess comorbidity in
greater depth, such as the PRISM or the SSADDA.
Interviewer training and experience enhance the
validity of ASI results (Mäkelä, 2004). Standardized
training is available and consists of a 2-day classroom
component and materials for independent study (see
www.tresearch.org/training/asi_train.htm).
Many community programs include the ASI in their
initial assessment battery, but informal reports suggest
that some look upon it as merely required paperwork
and use its information minimally, if at all, in treatment.
To remedy this situation, the NIDA/Substance Abuse
and Mental Health Services Administration (SAMHSA)
Blending Initiative has produced a curriculum on trans-
forming ASI data into clinically useful information (see
www.nida.nih.gov/Blending/ASI.html).
The Composite International Diagnostic Interview
The CIDI, originally developed by the World Health
Organization, assesses 22 DSM-IV diagnoses, includ-
ing mood, anxiety, and substance use disorders (see
“Alcohol Tolerance Item From the World Mental Health
Composite International Diagnostic Interview (WMH-
CIDI)”). For each substance use disorder, the CIDI elic-
its other information useful for treatment planning, such
as the patterns and course of alcohol and drug use.
The fully structured instrument takes  approximately
120 minutes to administer in its entirety (Kessler and
Ustün, 2004).
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Alcohol Tolerance Item From the World Mental Health Composite
International Diagnostic Interview (WMH-CIDI)
Source: Kessler and Ustün, 2004. Abbreviations: DK, don’t know; RF, refused.
Numbers are codes for recording the four responses.
YES   NO    DK    RF
(1)    (5)     (8)     (9)
ALCOHOL DEPENDENCE
Did you ever need to drink a
larger amount of alcohol to get
an effect, or did you ever find
that you could no longer get a
“buzz” or a high on the amount
you used to drink?
Various versions and adaptations of the original CIDI
have been developed. The University of Michigan ver-
sion, the UM-CIDI, has been used in a large interna-
tional epidemiological survey (Wittchen and Kessler,
1994), but appears to produce lower prevalence esti-
mates than other diagnostic instruments (Wittchen et
al., 1998). To address this problem and others related to
earlier versions of the CIDI, the World Mental Health
Survey Initiative Version, the WMH-CIDI, was devel-
oped (Kessler and Ustün, 2004). A complete descrip-
tion of WMH-CIDI modifications is reported elsewhere
(Kessler and Ustün, 2004). The WMH-CIDI is 
available in paper and computerized forms for down-
load or computer-assisted administration at www.
hcp.med.harvard.edu/wmhcidi/instruments.php.
Programs or projects may use the CIDI substance
use sections alone or combine them with other sections
to achieve the desired range of assessment. To meet the
particular needs of the substance abuse field, researchers
have developed the CIDI Substance Abuse Module
(CIDI-SAM), an expanded version of the original CIDI
substance use section that elicits detailed information
on such areas as the onset and history of substance abuse,
withdrawal symptoms, common comorbidities, social
consequences, and treatment history (Cottler, Robins,
and Helzer, 1989; Horton, Compton, and Cottler, 2000;
epi.wustl.edu/epi/assessments/sam.htm).
Test-retest studies of the original CIDI and the CIDI-
SAM paper versions have demonstrated good to excel-
lent reliability for DSM-IV diagnoses of any substance
use disorder or substance dependence and fair to good
reliability for abuse (Rubio-Stipec, Peters, and Andrews,
1999; Wittchen et al., 1998). The reliability of the CIDI,
version 3.0, was tested in the WHO World Mental Health
Surveys by comparing CIDI-derived diagnoses to those
derived with the SCID (Haro et al., 2006).  Concordance
for alcohol dependence (with or without abuse) was
excellent; concordance for drug dependence (with or
without abuse) was fair; and concordance for alcohol
abuse and drug abuse was good.
NIDA’s CTN adopted the CIDI after comparing
five commonly used substance use disorder diagnostic
instruments on 26 criteria, including psychometric prop-
erties, diagnostic time frames, time to administer, and
training and financial considerations (Forman et al.,
2004). The CTN workgroup ultimately determined that
only the CIDI met three crucial CTN requirements: it
can be administered by trained research technicians with
no prior clinical experience; it provides for DSM-IV, asR E S E A R C H   R E V I E W — A S S E S S I N G   A D D I C T I O N   •   2 5
TABLE 1. Characteristics and Selected Assessment Categories of Six Structured Assessment Instruments
* Assessment categories include Axis I and II disorders that commonly co-occur with abuse and dependence.
† Spanish language version available.
‡ Computerized version available.
§ The SCID features separate versions for Axis I and II disorders.
¶ Computerized version available in 2008.
Instrument
Addiction Severity
Index (ASI)† ‡
World Mental 
Health Composite
International
Diagnostic 
Interview (WMH-
CIDI)‡
Structured
Clinical Interview
for DSM-IV
(SCID)† ‡
Alcohol Use
Disorders
and Associated
Disabilities
Interview
Schedule
(AUDADIS)† ‡
Psychiatric
Research
Interview for
Substance and
Mental Disorders
(PRISM)†¶
Semi-Structured
Assessment for 
Drug Dependence
and Alcoholism
(SSADDA)‡
Diagnostic
Classification
No assess-
ment of diag-
nosis
Diagnostic and
Statistical Man-
ual of Mental
Disorders, 4th
Edition (DSM-
IV), Inter-
national Classi-
fication of
Diseases, 10th
Edition (ICD-
10)
DSM-IV
DSM-IV
DSM-IV
DSM-IV
Assessment Categories*
Functioning in 7 domains: alcohol, drugs, psychiatric, family/social,
medical, employment/support, legal
DSM-IV Alcohol/Drug Abuse and Dependence
ICD-10 Alcohol/Drug Dependence
ICD-10 Harmful Use Alcohol/Drugs
DSM-IV/ICD-10 Nicotine Dependence
DSM-IV/ICD-10 Anxiety Disorders
DSM-IV/ICD-10 Mood Disorders
DSM-IV Attention Deficit Disorder 
DSM-IV/ICD-10 Conduct Disorder
DSM-IV Intermittent Explosive Disorder 
DSM-IV/ICD-10 Pathological Gambling
Alcohol/Drug Dependence and Abuse, Polysubstance Dependence
Anxiety Disorders, Substance-Induced (S-I) Anxiety Disorders
Mood Disorders (Dysthymic Disorder, current only), S-I Mood Disorders
Acute Stress Disorder
Adjustment Disorder (current only)
Personality Disorder (Axis II version§)
Psychotic Disorders, S-I Psychotic Disorders
Somatization Disorder (current only)
Alcohol and Drug Consumption, Alcohol/Drug Abuse and Dependence
Tobacco Use and Dependence
Anxiety Disorders, S-I Anxiety Disorders
Mood Disorders, S-I Mood Disorders 
Pathological Gambling
Personality Disorders
Treatment Utilization (for each diagnosis), Family History (for each 
diagnosis) 
Alcohol/Drug Abuse and Dependence
Nicotine Dependence
Anxiety Disorders, S-I Panic Disorder, S-I Generalized Anxiety Disorder
Mood Disorders, S-I Mood Disorders
Antisocial Personality Disorder, Borderline Personality Disorder 
Psychotic Disorders, S-I Psychotic Disorders 
Alcohol/Drug Abuse and Dependence
Antisocial Personality Disorder
Attention Deficit Hyperactivity Disorder
Major Depression, Bipolar Disorder
Pathological Gambling 
Post-Traumatic Stress Disorder
Time Frames
Covered by the
Assessments
Lifetime, past 
30 days
Lifetime, past 
12 months
Lifetime, current
Lifetime, past 
12 months
Lifetime, past 
12 months, 
current
Lifetime
Average Administra-
tion Time in Psychia-
tric Populations
45-60 min., plus 
10-20 min. for 
scoring
75 min.
90 min.
No information 
available
120 min.
No information 
available
Training
Training manual, class-
room session (2 days),
competency measures
administered at end of
each session
Home-study CDs,
classroom training 
(2.5-3 days)
User’s guide, 
didactic recordings 
(11 hours), interview
recordings, on-site
training (1-2 days),
audiotape review for 
quality assurance
Not available 
Training manual, didac-
tic session (2 days),
audiotape review for
quality assurance
Training manual, didac-
tic session (3 days),
audiotape review for
quality assurance2 6 •   A D D I C T I O N   S C I E N C E   &   C L I N I C A L   P R A C T I C E — D E C E M B E R   2 0 0 7
ALCOHOL USE SCREENING
What are your drinking habits like?
How much do you drink? 
Has there ever been a time in your life when you had five or more 
drinks on one occasion?
When in your life were you drinking the most?
How long did that period last?
During that time…
How often were you drinking?
What were you drinking? How much?
During that time…
Did your drinking cause problems for you?
Did anyone object to your drinking?
Alcohol Use Screening From the Structured Clinical Interview 
for DSM (SCID)
Sources: First et al., 2002; Williams et al., 1992.
well as International Classification of Diseases, 10th Edition
(ICD-10; World Health Organization, 1993), substance
use disorder diagnoses; and it provides for past-year and
lifetime diagnoses. At this point, it is too soon to
know whether CTN-related community-based programs
will adopt the CIDI for clinical use. 
The Structured Clinical Interview for DSM-IV
The SCID is available in different versions for researchers
and clinicians. Additionally, the research version is avail-
able in formats for patients, nonpatients, and patients
with psychotic disorders. The Structured Clinical Inter-
view for DSM-IV-TR Axis I Disorders, Research Version,
Patient Edition (First et al., 2002), provides lifetime and
current diagnostic assessments for many DSM-IV dis-
orders, including substance use disorders. The sepa-
rate SCID for Axis II disorders provides the basis for
diagnosing personality disorders (First et al., 1997).
The semi-structured SCID is designed for adminis-
tration by interviewers with clinical expertise, but 
research assistants having extensive experience with a
population under study have sometimes learned to 
administer it successfully. After an open-ended overview
and brief general screening, the interviewer takes the
patient through the questions on the form, following
up as needed (based on clinical judgment) to clarify
responses. The alcohol and drug modules contain open-
ended screening questions as well (see “Alcohol Use
Screening From the Structured Clinical Interview for
DSM (SCID)”). Administration can take up to several
hours, depending on the complexity of the patient’s 
substance and psychiatric history. The instrument is
modular, so clinicians can make use of only those sec-
tions that pertain to assessment aims. It contains a min-
imal number of nondiagnostic items to keep adminis-
tration time as brief as possible. 
In tests among substance-abusing populations, the
SCID has demonstrated excellent reliability for diag-
nosing DSM-III-R substance dependence (American
Psychiatric Association, 1987; Ross et al., 1995). A small
test-retest study of 52 patients with DSM-IV diagnoses
showed excellent reliability for substance use disorders
(Zanarini et al., 2000). The SCID Web site (www.
scid4.org/index.html) provides information on the dif-
ferent versions, psychometric properties, ways to obtain
copies of the interview and training materials, and pro-
cedures for arranging on-site training. A user’s guide pro-
vides basic training in the use of the SCID. In addition,
an 11-hour videotape training program is available with
examples of interviews with actual patients. The instru-
ment’s developers recommend at least 20 hours of train-
ing on the full SCID for most clinicians. A Spanish-
language version of the SCID (research version), in which
only the questions have been translated, and a computer-
assisted SCID (for Axis I disorders, clinician version),
developed by an outside source, can be obtained through
the SCID Web site.
The Alcohol Use Disorder and Associated
Disabilities Interview Schedule
The AUDADIS (Grant et al., 1995, 2003) provides for
current (last 12 months) and lifetime DSM-IV diag-
noses of major mood, anxiety, personality, and substance
use disorders. Originally developed by the National
Institute on Alcohol Abuse and Alcoholism (NIAAA)
for use in population-based epidemiological surveys, the
fully structured AUDADIS functions as an economical
tool that lay staff in treatment programs can administer
for intake screening. Clinicians can use the detailed
descriptive data obtained by the AUDADIS to structure
treatment based on a patient’s specific substance-related
behaviors. In addition to alcohol, tobacco, and other
drug use, modules address treatment and family history.
Numerous queries address the frequency and quantity
of use of each type of alcohol (e.g., beer, wine, liquor)
and each illicit drug during three time periods—that of
heaviest use, the past 12 months, and the interviewee’s
lifetime (see “Sample Item From the Alcohol Use Dis-
order and Associated Disabilities Interview Schedule
(AUDADIS)”).A recent test-retest study of 285 heavy substance
users showed good to excellent reliability for most 
dependence diagnoses, including alcohol, cocaine, heroin,
cannabis, and sedative dependence (Hasin et al., 2006a).
An independently conducted validity study of a Spanish-
language version of the PRISM with the Longitudinal,
Expert, All-Data Diagnosis (LEAD) procedure (Spitzer,
1983) as the “gold standard” and the SCID found that
the concordance of the three assessments in substance
dependence was good to excellent. However, PRISM/LEAD
concordance was significantly better than SCID/LEAD
concordance on current cannabis and cocaine depend-
ence, as well as past alcohol abuse and dependence (Torrens
et al., 2004). The English version of the PRISM can
be downloaded, together with training information
(www.columbia.edu/~dsh2/prism). A computer-assisted
version, which will include questions on marijuana with-
drawal and modules for nicotine-related disorders, patho-
logical gambling, and attention deficit hyperactivity dis-
order, will be available in 2008. 
The Semi-Structured Assessment for Drug
Dependence and Alcoholism
The SSADDA (Pierucci-Lagha et al., 2005) was devel-
oped for use in studies of genetic influences on cocaine
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Sample Item From the Alcohol Use Disorder and Associated
Disabilities Interview Schedule (AUDADIS)
Sources: Grant et al., 1995, 2003.
1 __ Every day
2 __ Nearly every day
3 __ 3 to 4 times a week
4 __ 2 times a week
5 __ Once a week
6 __ 2 to 3 times a month
7 __ Once a month
8 __ 7 to 11 times in the last year
9 __ 3 to 6 times in the last year
10 __ 1 or 2 times in the last year
Now I’d like to ask you about
drinking beer.
5a. During the last 12 months,
did you drink any beer, light
beer or malt liquor? Do not
count nonalcoholic beers.
Statement D
5b.(SHOW FLASHCARD 12)
During the last 12 months,
about how often did you drink
any beer or malt liquor?
1 __ Yes
2 __ No – SKIP to Statement E, 
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The AUDADIS showed high reliability in a test-
retest study in clinical settings where comorbidity was
expected to be high (Hasin et al., 1996). Its test-
retest reliabilities for alcohol and drug consumption,
abuse, and dependence, as well as those for other mod-
ules, were good to excellent (Grant et al., 1995, 2003).
The AUDADIS interview can be downloaded (niaaa.
census.gov/questionaire.html). The instrument’s devel-
opers recommend using the computer-assisted version.
The Psychiatric Research Interview for Substance
and Mental Disorders
The PRISM (Hasin et al., 1996, 2006a; Hasin, Trautman,
and Endicott, 1998) is a semi-structured diagnostic inter-
view designed expressly for assessing comorbid psychi-
atric disorders in individuals who abuse substances. The
instrument’s strength is in differentiating independent
psychiatric disorders, such as depression, from the effects
of intoxication and withdrawal. Along with abuse and
dependence diagnoses for specific substance categories,
clinicians and researchers can use the PRISM to make
current and lifetime DSM-IV diagnoses of Axis I and
Axis II disorders that commonly occur with substance
abuse, such as mood, anxiety, and psychotic disorders.
The PRISM sections on substance use disorders are
placed at the beginning of the interview and provide a
background for the overall clinical picture. Periods of
chronic intoxication (defined as “at least 4 days a week
for a month”) or binge use (defined as “most of the
day for 3 or more days”) and extended periods of absti-
nence are identified and charted on a timeline. The time-
line is the only part of the PRISM that is conducted in
an unstructured format, and timeline information is not
coded for data entry. The purpose of the timeline is to
assist in differentiating primary versus substance-induced
symptoms in later diagnostic sections. 
PRISM developers incorporated two features into
the instrument to avoid the lengthy administration time
associated with many standardized interviews. First,
diagnostic sections are modular, so the instrument can
be tailored to fit specific treatment or research needs.
Second, consumption questions in the substance use
module do not seek detailed information about patterns,
but simply ask how often the interviewee has used the
substance “in the last 12 months” or “ever” and whether
the individual has ever experienced a period of chronic
intoxication or binge use. If the response to any of these
broad questions is “yes,” the interviewer moves on to the
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and opioid dependence. Derived from the Semi-Structured
Assessment for the Genetics of Alcoholism, the SSADDA
provides extensive coverage of the physical, psycholog-
ical, social, and psychiatric manifestations of cocaine
and opioid abuse and dependence in addition to a num-
ber of related Axis I and Axis II disorders. A standout
feature of the SSADDA is its inclusion of questions about
the onset and recency of individual alcohol and drug
symptoms, permitting a temporal assessment of symp-
tom clusters. Information about the timing of symp-
toms is particularly helpful in distinguishing comorbid
disorders from intoxication or withdrawal effects. 
The reliability of individual dependence criteria in
the SSADDA has been tested to determine the extent
to which independent interviewers arrive at the same
diagnostic conclusions. Overall, the inter-rater reliabil-
ity estimates were excellent for individual DSM-IV cri-
teria for nicotine and opioid dependence; good for alco-
hol and cocaine dependence; and fair for dependence
on cannabis, sedatives, and stimulants (Pierucci-Lagha
et al., 2007). A computer-assisted version of the SSADDA
is available free. Further information can be obtained
by contacting Dr. Amira Pierucci-Lagha, Alcohol Research
Center, Department of Psychiatry, University of Con-
necticut School of Medicine.
CONCLUSION
The publication of the DSM-III ushered in a period
of standardized assessment and diagnosis in mental health
research. Several widely used structured and semi-
structured instruments for assessing dependence, co-
occurring psychiatric disorders, and associated problems
have shown good reliability, validity, and acceptance
in clinical research settings. These instruments are now
being used in community settings to inform treatment
planning and case management. 
Regardless of their original purposes, all of the meas-
ures described in this paper can be used for both research
and treatment. The decision to use one instrument rather
than another will depend on a number of practical con-
siderations. Reliability and validity often vary consid-
erably between specific drug categories. Thus, a review
of the strength of the specific drug diagnoses of interest
is important. Users will need to consider whether dis-
orders other than substance use or other characteris-
tics of interest are covered and, when necessary, if the
instrument is available in a language other than English.
Staff level of experience and training costs are also key
factors in evaluating the appropriateness of an instru-
ment for a particular research or treatment setting. 
Most of the measures are in modular format. Substance
disorder and other modules, along with a measure of
problem severity like the ASI, can serve as the basis of
a thorough intake interview and, as the patient progresses
through treatment, can be used to assess changes in sta-
tus systematically. Modules from different instru-
ments can be combined, but this can be complicated if
computer-assisted versions are used. In addition, even
the most user-friendly computer-assisted instruments
require staff with technical know-how, and computer
and software costs and licensing fees can be high in rela-
tion to budget allowances. Conversely, paper-and-pen-
cil versions consume additional staff time for data clean-
ing and data entry, require repeated printing, and can
take up a great deal of storage space, depending on the
sample or patient population size. Thus, a thorough cost
estimate is needed before deciding whether to use a paper-
and-pencil or computerized format. 
The SSADDA
was developed
for studies 
of genetic
influences on
cocaine and
opioid
dependence.
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RESPONSE: ASSESSING THE INSTRUMENTS
Jack D. Blaine, M.D.; Robert F. Forman, Ph.D.; and Dace Svikis, Ph.D.
Jack Blaine:Except for the ASI, the instru-
ments discussed in the article (Samet et al.,
2007) were developed for research. The
AUDADIS, as the authors note, was cre-
ated for use in large-scale epidemiological
research in the general population. It’s a very
fine, fully structured interview. A research
assistant with no clinical training can make
valid diagnoses. The SCID and the PRISM
were developed to be administered by expe-
rienced clinicians. These interviews take
longer, though, so they’re not practical for
larger-scale research. The CIDI was also
developed for epidemiological research,
though we use it in clinical settings.
Dace Svikis: In research, we use these for-
mal structured assessment instruments to
characterize our population. As the authors
illustrate with their example of depression
studies, we need to know what substance
use and other psychiatric diagnoses partic-
ipants have so that our analyses don’t miss
any factors that affect outcomes.
Robert Forman: The use of formal struc-
tured assessment instruments is absolutely
critical for research. Even in research, how-
ever, they must be used judiciously, because
patients’ reactions to them can affect clini-
cal outcomes and possibly confound the
interpretation of results (e.g., Clifford, Maisto,
and Davis, 2007). To me, the justification
for using them in clinical practice hasn’t
been established.
Blaine:Except for the ASI, the instruments
discussed in the article take too much time
to administer to be practical for routine clin-
ical use. They also often require extensive
training and monitoring for fidelity to ensure
that clinicians continue to use the measures
in line with the practice guidelines.
Data quality and therapeutic alliance
Svikis:The move toward the clinical use of
standardized instruments was spearheaded
by concern that some clinicians were not
doing a thorough job of collecting patient
information. Dr. A. Thomas McLellan has
said that this was his original motivation for
developing the ASI. He had noted that, for
example, some clinicians were asking patients
about depression, and others weren’t.
Standardized instruments make sure that
all clinicians obtain a uniform set of basic
patient data. At the same time, we need to
recognize that there are many really good
drug counselors with excellent clinical skills.
Those counselors can feel handcuffed by
structured instruments.
Forman: You have to be extremely talented
to go through a structured interview, even
one that is semi-structured, and maintain
a therapeutic alliance. Fully structured 
interviews have a tendency to become robo-
tic, when what clients want is someone who’s
going to listen and understand them—some-
one they can open up to.
Svikis:The way fully structured instruments
work, if you follow the administration guide-
lines, when a patient doesn’t understand
what you’re saying, you can only repeat the
question verbatim. You can’t add informa-
tion or paraphrase. That makes it hard to
establish empathy. It is easier to establish a
rapport with semi-structured instruments
like the ASI.
Another feature of fully structured instru-
ments that makes them aversive is that you
have to repeat all the same questions for each
potential drug of abuse. In a clinical setting
where the average person uses six or seven
substances, that makes for a very long and
tedious interview. It’s quite different from
using the instruments in an epidemiologi-
cal context with a focus on the general pop-
ulation, where most people use one or
two substances regularly or none at all.
Blaine: There is no question that it’s easier
to establish a relationship with a patient
with a less structured instrument than with
a more rigid one. Still, the very act of gath-
ering information shows that you are inter-
ested in finding out about a person’s prob-
lems. I think that builds rapport.
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